Company

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals develops therapies for cardiometabolic diseases, including obesity and MASH.

About

NeuroBo Pharmaceuticals is developing DA-1726 and DA-1241, clinical-stage candidates for obesity and MASH. The company is based in Boston and targets patients in North America and Europe. Founded in 2017, it raised USD 14.000 mn in a Private Placement/Follow on round in October 2021.

2Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in